Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

• Main Authors: Peter Chang (Author), Vidya Perera (Author), David H. Salinger (Author), Samira Merali (Author), Neelima Thanneer (Author), Hyunmoon Back (Author), Julie D. Seroogy (Author), Daniel D. Gretler (Author), Amy J. Sehnert (Author), Maria Palmisano (Author), Amit Roy (Author)
• Format: Book
• Published: Wiley, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Mavacamten is a selective, allosteric, reversible cardiac myosin inhibitor that has been developed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). A population pharmacokinetic (PopPK) model was developed to characterize mavacamten pharmacokinetics...